UPDATE - Barclays Initiates Coverage on Campus Crest Communities (CCG) with an Equalweight; Underserved Markets, But Low Barrier of Entry
Get Alerts CCG Hot Sheet
Price: $16.13 +0.81%
Rating Summary:
2 Buy, 5 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Rating Summary:
2 Buy, 5 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 6 | New: 26
Join SI Premium – FREE
UPDATE - Barclays initiates coverage on Campus Crest Communities (NYSE: CCG) with an Equalweight. PT $12.00.
Analyst, Ross L. Smotrich, said, "CCG targets smaller colleges than its public peers; as a result it builds in secondary and tertiary markets. These markets typically have relatively little purpose-built student housing and have low-cost land available for development. As such, CCG is able to develop to unlevered yields in the 7.25-8.25% range; in our model we assume it develops to 7.5% yields."
However, Smotrich noted that just because the company focuses on smaller colleges and secondary markets, doesn't mean competitors can or will move in. Also, the company is relatively small vs. peers, so operational missteps could hinder growth.
To see more ratings on CCG, Click Here
Analyst, Ross L. Smotrich, said, "CCG targets smaller colleges than its public peers; as a result it builds in secondary and tertiary markets. These markets typically have relatively little purpose-built student housing and have low-cost land available for development. As such, CCG is able to develop to unlevered yields in the 7.25-8.25% range; in our model we assume it develops to 7.5% yields."
However, Smotrich noted that just because the company focuses on smaller colleges and secondary markets, doesn't mean competitors can or will move in. Also, the company is relatively small vs. peers, so operational missteps could hinder growth.
To see more ratings on CCG, Click Here
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Emkay Global Starts Urban Company (URBANCO:IN) at Buy (1)
- TD Cowen Assumes Atara Biotherapeutics (ATRA) at Buy
- TD Cowen Assumes Maze Therapeutics (MAZE) at Buy
Create E-mail Alert Related Categories
New CoverageRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share